Total Funding
1
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
2353998
Diurnal Group is a pharmaceutical company creating therapeutic drugs used for the endocrine hormone area.
Richard Ross: Founding Director & CSOPast Role: Barts Health NHS Trust, Senior Lecturer
Martin Whitaker: General Manager
About the Company
Diurnal is an innovative pharmaceutical company that creates high-value therapeutics using advanced proprietary formulations and novel physiological treatment regimes of approved drugs for use in the endocrine (hormone) area.
Founded in 2004, Diurnal is headquartered in Cardiff, United Kingdom, and is a specialty pharma company developing hormone
therapeutics for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
